Artesunate Clinical Trials

Size	Price	Qty
10mg	USD 147
50mg	USD 247

Clinical Trials

Artesunate is evaluated across numerous Phase 1 to Phase 4 clinical trials, examining therapeutic utility in severe and drug-resistant Plasmodium falciparum malaria, viral infections such as COVID-19, and non-communicable conditions including anal high-grade squamous intraepithelial lesions, Friedreich ataxia, idiopathic pulmonary fibrosis, and chronic myeloid leukemia. Sponsored by diverse organizations—including the London School of Hygiene and Tropical Medicine, INSERM, and Pfizer—these studies encompass recruiting, active non-recruiting, and completed statuses to evaluate treatment efficacy across varied disease stages.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07095309	NOT_YET_RECRUITING	Stage II/III Colon Cancer; Bowel Cancer	Metanoic Health Ltd.	2025-08-15	PHASE2
NCT06872112	RECRUITING	Pulmonary Arterial Hypertension (PAH)	Joseph C. Wu	2026-04-01	PHASE1
NCT05988463	RECRUITING	Idiopathic Pulmonary Fibrosis	Joseph C. Wu	2026-08-01	PHASE1
NCT06962319	RECRUITING	Malaria, Pregnancy; Malaria, Antepartum; Malaria (Uncomplicated)	Liverpool School of Tropical Medicine	2025-09-30	PHASE3
NCT07060794	NOT_YET_RECRUITING	Vivax Malaria	Menzies School of Health Research	2026-06	PHASE4
NCT06853184	RECRUITING	CMV Infection	Amivas Inc.	2025-08-01	PHASE2
NCT06967519	RECRUITING	Malaria; Hiv	Yale University	2025-12-18	PHASE4
NCT07470424	NOT_YET_RECRUITING	Malaria	University of Oxford	2026-11-01	PHASE1
NCT07095478	NOT_YET_RECRUITING	CIN 2/3	Metanoic Health Ltd.	2025-08-01	PHASE2
NCT06206564	RECRUITING	Anal High-grade Squamous Intraepithelial Lesion; Anal HSIL; Anal HPV Infection; AIN	Frantz Viral Therapeutics, LLC	2024-01-12	PHASE2
NCT05555862	ACTIVE_NOT_RECRUITING	Anal High Grade Squamous Intraepithelial Lesion; Anal Precancerous Condition; AIN 2/3; HPV Infection; Anal Dysplasia; HPV Disease	Frantz Viral Therapeutics, LLC	2023-02-10	PHASE2
NCT06075264	RECRUITING	Vulvar Diseases; HPV Infection; Vulvar HSIL; Pre-Cancerous Dysplasia; HPV Disease; VIN, Usual Type; VIN 2 of Usual Type; VIN 3 of Usual Type; Vin II; Vin III; VIN Grade 2; VIN Grade 3; High Grade Intraepithelial Neoplasia	Frantz Viral Therapeutics, LLC	2023-12-06	PHASE2
NCT04098744	RECRUITING	CIN 2/3; HPV Infection; Pre-Cancerous Dysplasia; Cervical Dysplasia; HPV Related Disease	Frantz Viral Therapeutics, LLC	2020-09-09	PHASE2
NCT05951595	RECRUITING	Uncomplicated Plasmodium Falciparum Malaria	University of Oxford	2025-09-11	PHASE3
NCT07022743	ACTIVE_NOT_RECRUITING	Chronic Myeloid Leukemia (CML)	Obafemi Awolowo University	2025-07-01	PHASE2
NCT05441410	NOT_YET_RECRUITING	Malaria	University Hospital Tuebingen	2025-06-01	PHASE1; PHASE2
NCT06519994	COMPLETED	Human Immunodeficiency Virus; Human Papillomavirus; Cervical Precancer	UNC Lineberger Comprehensive Cancer Center	2025-01-22	PHASE2
NCT04675931	COMPLETED	Severe Malaria	Novartis Pharmaceuticals	2022-03-07	PHASE2
NCT05750459	COMPLETED	Plasmodium Falciparum Infection	National Institute of Allergy and Infectious Diseases (NIAID)	2023-11-29	PHASE4
NCT06165614	COMPLETED	Cervix Cancer; Cervix Neoplasm; Precancerous Conditions; Cervical Precancer	UNC Lineberger Comprehensive Cancer Center	2024-03-04	PHASE1
NCT06294912	COMPLETED	Malaria	Merck Sharp & Dohme LLC	2024-04-18	PHASE1
NCT05929157	UNKNOWN	Severe Malarial Treatment	Centre de Recherche Médicale de Lambaréné	2023-09-01	PHASE1; PHASE2
NCT05764746	COMPLETED	Uncomplicated Plasmodium Falciparum Malaria	Muhimbili University of Health and Allied Sciences	2023-05-01	PHASE2; PHASE3
NCT04706130	COMPLETED	Vivax Malaria	University of Maryland, Baltimore	2021-04-15	PHASE4
NCT06076213	COMPLETED	Uncomplicated Plasmodium Falciparum Malaria	Ministry of Public Health, Democratic Republic of the Congo	2023-05-01	PHASE4
NCT06263582	COMPLETED	Cervix Cancer; Cervix Intraepithelial Neoplasia Grade 3; Cervix; Intraepithelial Neoplasia, Grade I; Cervix; Intraepithelial Neoplasia, Grade II	UNC Lineberger Comprehensive Cancer Center	2024-05-29	PHASE1
NCT04921930	COMPLETED	Friedreich Ataxia	Institut National de la Santé Et de la Recherche Médicale, France	2022-05-06	PHASE1; PHASE2
NCT03923725	COMPLETED	Plasmodium Falciparum Malaria (Uncomplicated)	University of Oxford	2020-09-01	PHASE3
NCT04330690	UNKNOWN	COVID-19	Sunnybrook Health Sciences Centre	2020-03-18	PHASE3
NCT04713631	UNKNOWN	Crohn's Disease	Sanjay Gandhi Postgraduate Institute of Medical Sciences	2021-01-21	PHASE2
NCT05343312	COMPLETED	Malaria	Centro de Investigacao em Saude de Manhica	2022-03-16	PHASE4
NCT05929157	Not yet recruiting	Severe Malarial Treatment	Centre de Recherche Médicale de Lambaréné\|Institute of Tropical Medicine University of Tuebingen	2023-09-01	Phase 1\|Phase 2
NCT06300970	COMPLETED	Plasmodium Falciparum; Malaria; Uncomplicated Malaria	Centers for Disease Control and Prevention	2022-08-09	PHASE4
NCT06472258	COMPLETED	Malaria	RESnTEC, Institute of Research	2023-03-01
NCT05555862	Active not recruiting	Anal High Grade Squamous Intraepithelial Lesion\|Anal Precancerous Condition\|AIN 2/3\|HPV Infection\|Anal Dysplasia\|HPV Disease	Frantz Viral Therapeutics LLC\|Amarex CRO\|University of California San Francisco\|Anal Dysplasia Clinic MidWest\|Laser Surgery Care	2023-02-10	Phase 2
NCT03939104	COMPLETED	Plasmodium Falciparum Malaria (Uncomplicated)	University of Oxford	2021-06-30	PHASE3
NCT02633098	UNKNOWN	Colorectal Cancer; Bowel Cancer	St George's, University of London	2017-04-26	PHASE2
NCT05550909	COMPLETED	Malaria,Falciparum	London School of Hygiene and Tropical Medicine	2022-10-17	PHASE2
NCT05273242	UNKNOWN	COVID-19	Nepal Health Research Council	2021-12-06	PHASE4
NCT04695197	COMPLETED	Covid-19; Malaria	Liverpool School of Tropical Medicine	2021-01-08	PHASE3
NCT03214731	UNKNOWN	Lupus Nephritis	Sun Yat-sen University	2019-01-16	PHASE4
NCT04387240	WITHDRAWN	Covid 19 Positive; Corona Virus Infection	Princess Nourah Bint Abdulrahman University	2022-01	PHASE2
NCT03792516	COMPLETED	Vulvar Dysplasia; HPV-Related Vulvar Intraepithelial Neoplasia; Preinvasive Vulvar Disease; Vulva Intraepithelial Neoplasia; Vulvar Diseases	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	2019-04-17	PHASE1
NCT03726593	UNKNOWN	Plasmodium Falciparum Malaria (Drug Resistant)	Armed Forces Research Institute of Medical Sciences, Thailand	2018-10-04	PHASE4
NCT05140278	COMPLETED	Severe Malaria	University of Oxford	2022-07-18	PHASE2
NCT04783051	COMPLETED	Malaria in Pregnancy	University of Kinshasa	2021-05-06	PHASE3
NCT04921930	Recruiting	Friedreich Ataxia	Institut National de la Santé Et de la Recherche Médicale France\|Imagine Institute	2022-05-06	Phase 1\|Phase 2
NCT04701606	UNKNOWN	Covid19	Shin Poong Pharmaceutical Co. Ltd.	2021-03-29	PHASE2; PHASE3
NCT05343312	Active not recruiting	Malaria	Centro de Investigacao em Saude de Manhica\|United States Agency for International Development (USAID)	2022-03-16	Phase 4
NCT04618523	COMPLETED	Malaria	Ministry of Public Health, Democratic Republic of the Congo	2020-10-26	PHASE4
NCT04829695	UNKNOWN	Falciparum Malaria	University of Yaounde 1	2021-04-05	PHASE4
NCT03093129	UNKNOWN	Colorectal Cancer	The 108 Military Central Hospital	2018-01-08	PHASE2
NCT03100045	COMPLETED	HPV-Related Anal Intraepithelial Neoplasia; AIN2/3; Artesunate; Alternative Treatment; Anal Dysplasia; Precancerous Conditions; Human Papilloma Virus	Johns Hopkins University	2017-04-20	PHASE1
NCT04532931	COMPLETED	COVID-19	Shin Poong Pharmaceutical Co. Ltd.	2020-09-03	PHASE2
NCT04475107	COMPLETED	COVID-19	Shin Poong Pharmaceutical Co. Ltd.	2020-07-09	PHASE2
NCT03893097	COMPLETED	Schistosoma Haematobium; Schistosoma Mansoni	Institute of Tropical Medicine, Belgium	2019-10-14	PHASE3
NCT03640403	COMPLETED	Malaria,Falciparum; Anemia	National Institute for Medical Research, Tanzania	2019-03-26	PHASE3
NCT05192265	COMPLETED	Malaria Fever; Plasmodium Falciparum Malaria; Uncomplicated Malaria	University of Ibadan	2019-05-20	PHASE2; PHASE3
NCT04374019	TERMINATED	COVID; Sars-CoV2	Susanne Arnold	2020-05-01	PHASE2
NCT04565184	COMPLETED	Malaria,Falciparum	University of Yaounde 1	2019-05-09	PHASE4
NCT04049916	COMPLETED	Malaria,Falciparum	London School of Hygiene and Tropical Medicine	2019-09-12	PHASE2; PHASE3
NCT04264130	COMPLETED	Schistosomiasis Haematobia	Centre de Recherche Médicale de Lambaréné	2018-07-31	PHASE2
NCT03814616	UNKNOWN	Malaria,Falciparum	Shin Poong Pharmaceutical Co. Ltd.	2018-10-03	PHASE2
NCT03201770	COMPLETED	Malaria,Falciparum	Shin Poong Pharmaceutical Co. Ltd.	2017-06-22	PHASE4
NCT02663700	COMPLETED	Plasmodium Falciparum Infection	National Institute of Allergy and Infectious Diseases (NIAID)	2016-04-07	PHASE1
NCT02612545	COMPLETED	Acute Falciparum Malaria	National Institute of Allergy and Infectious Diseases (NIAID)	2015-11-20	PHASE1
NCT04370977	COMPLETED	Malaria	Centro de Investigacao em Saude de Manhica	2018-03-21	PHASE4
NCT02354534	COMPLETED	Cervical Intraepithelial Neoplasia Grade 2/3; High-risk HPV (Any Strain)	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	2015-02	PHASE1
NCT02996695	COMPLETED	Plasmodium Falciparum Infection	National Institute of Allergy and Infectious Diseases (NIAID)	2017-04-06	PHASE1
NCT02940756	COMPLETED	Malaria	Ministry of Public Health, Democratic Republic of the Congo	2017-03-15	PHASE4
NCT03431714	COMPLETED	Uncomplicated Falciparum Malaria	National Institute for Medical Research, Tanzania	2017-07-14	PHASE4
NCT03773536	COMPLETED	Plasmodium Falciparum Malaria	Professor Anders Björkman	2017-05-09	PHASE4
NCT02411994	COMPLETED	Malaria	Royal Tropical Institute	2015-10	PHASE3
NCT01640587	TERMINATED	P. Falciparum Malaria	University of Oxford	2013-11
NCT02304289	TERMINATED	Hepatocellular Carcinoma	University Hospital, Ghent	2014-11	PHASE1
NCT02851108	COMPLETED	Malaria, Falciparum	Heidelberg University	2016-10	PHASE2
NCT02242799	COMPLETED	Malaria; HIV	University of Liverpool	2015-06	PHASE1
NCT01054248	COMPLETED	Malaria	University of Oxford	2010-02-16	PHASE3
NCT02604966	UNKNOWN	Drug Resistant Malaria Due to Plasmodium Falciparum	National Institute of Malariology, Parasitology and Entomology, Vietnam	2015-04	PHASE4
NCT02653898	UNKNOWN	Malaria; Parasitic Diseases	Armed Forces Research Institute of Medical Sciences, Thailand	2016-01	PHASE4
NCT02389439	COMPLETED	Malaria, Falciparum	University of Oxford	2015-03-01	PHASE2
NCT02353026	COMPLETED	Solid Tumors	Georgetown University	2015-01	PHASE1
NCT02297477	UNKNOWN	Malaria	Armed Forces Research Institute of Medical Sciences, Thailand	2014-12	PHASE4
NCT02084602	COMPLETED	Malaria, Falciparum	Instituto Nacional de Salud. Peru	2014-06-18	PHASE4
NCT02052323	COMPLETED	Malaria	Armed Forces Research Institute of Medical Sciences, Thailand	2013-10	PHASE4
NCT02492178	COMPLETED	Malaria	University of Oxford	2015-07	PHASE2
NCT01955382	COMPLETED	Malaria; Severe Malaria	National Institute of Allergy and Infectious Diseases (NIAID)	2013-09	PHASE2
NCT02092766	COMPLETED	Anaemia	University of Oxford	2014-06	PHASE4
NCT01662700	UNKNOWN	Acute Uncomplicated Malaria With P.Vivax Infection	Mahidol University	2012-10	PHASE4
NCT01708876	COMPLETED	Uncomplicated Plasmodium Knowlesi Malaria	Menzies School of Health Research	2012-10	PHASE3
NCT01976780	COMPLETED	Malaria	Global Emerging Infections Surveillance and Response System	2013-06	PHASE4
NCT02741024	COMPLETED	Malaria	Medecins Sans Frontieres, Netherlands	2013-10	PHASE4
NCT01755559	COMPLETED	Malaria	Epicentre	2013-06	PHASE4
NCT01697787	COMPLETED	Malaria	Centre Muraz	2012-10	PHASE4
NCT02637128	COMPLETED	MALARIA, FALCIPARUM	Centers for Disease Control and Prevention	2014-03	PHASE4
NCT01374581	COMPLETED	Malaria	Universiteit Antwerpen	2012-05	PHASE3
NCT01350856	COMPLETED	Falciparum Malaria	University of Oxford	2011-05	PHASE4
NCT01845701	COMPLETED	Malaria	University of Yaounde 1	2010-03	PHASE3
NCT02563704	COMPLETED	Malaria	University of Yaounde 1	2013-09	PHASE3
NCT01707199	COMPLETED	Uncomplicated P. Falciparum Malaria	University of Oxford	2012-10
NCT01967472	COMPLETED	Malaria	London School of Hygiene and Tropical Medicine	2013-09-16
NCT01939886	COMPLETED	Malaria	London School of Hygiene and Tropical Medicine	2013-04	PHASE3
NCT00764036	COMPLETED	Metastatic Breast Cancer; Locally Advanced Breast Cancer	Heidelberg University	2008-10	PHASE1
NCT01868438	COMPLETED	Malaria	Medicines for Malaria Venture	2013-05	PHASE1
NCT00852423	COMPLETED	Malaria in Pregnancy	Institute of Tropical Medicine, Belgium	2010-06	PHASE3
NCT01023399	COMPLETED	Malaria	Sanofi	2009-11	PHASE4
NCT01378286	COMPLETED	Malaria	Sanofi	2012-01	PHASE3
NCT02974348	COMPLETED	Drug Resistant Malaria Due to Plasmodium Falciparum	University of Bamenda	2013-01	PHASE3
NCT01805232	UNKNOWN	Malaria	University of Khartoum	2013-03	PHASE4
NCT01319448	COMPLETED	Malaria; Sickle Cell Crisis	London School of Hygiene and Tropical Medicine	2011-09	PHASE1; PHASE2
NCT01144702	COMPLETED	Falciparum Malaria	Oswaldo Cruz Foundation	2010-11	PHASE2; PHASE3
NCT01231113	COMPLETED	Pregnancy Complicated by Malaria as Antepartum Condition	Kwame Nkrumah University of Science and Technology	2011-07	PHASE3
NCT01374126	COMPLETED	Falciparum Malaria	Medical University of Vienna	2011-07	PHASE2
NCT01552330	COMPLETED	Healthy	University of Oxford	2012-05	PHASE1
NCT01074905	COMPLETED	Vivax Malaria	University of Oxford	2010-05	PHASE3
NCT01523002	COMPLETED	Malaria	Medicines for Malaria Venture	2012-01	PHASE1
NCT01326754	COMPLETED	Malaria, Falciparum	Centers for Disease Control and Prevention	2011-08
NCT01288820	COMPLETED	Vivax Malaria	University of Oxford	2011-01	PHASE3
NCT01107145	TERMINATED	Plasmodium Vivax Malaria	Centers for Disease Control and Prevention	2011-02	PHASE4
NCT02168569	COMPLETED	Malaria	Centro de Investigacao em Saude de Manhica	2011-06	PHASE4
NCT01082731	TERMINATED	Malaria	Centers for Disease Control and Prevention	2010-11	PHASE4
NCT01190371	UNKNOWN	Malaria	KEMRI-Wellcome Trust Collaborative Research Program	2011-04	PHASE4
NCT01407887	COMPLETED	Uncomplicated Falciparum Malaria	Heidelberg University	2011-08	PHASE2
NCT01165372	COMPLETED	Malaria	Oxford University Clinical Research Unit, Vietnam	2010-08	PHASE2
NCT01213433	COMPLETED	Uncomplicated Malaria	Centre Muraz	2010-10	PHASE4
NCT00988507	TERMINATED	Plasmodium Falciparum Infection	Sanofi	2009-10	PHASE2
NCT01152931	COMPLETED	Malaria	University of Lagos, Nigeria	2010-08	PHASE3
NCT04368910	TERMINATED	Malaria	Medicines for Malaria Venture	2007-09-06	PHASE3
NCT00936767	WITHDRAWN	Uncomplicated Falciparum Malaria	University of Oxford	2010-10	PHASE2; PHASE3
NCT00808951	COMPLETED	Malaria	Centre Muraz	2008-12	PHASE4
NCT01082718	WITHDRAWN	Malaria; Pregnancy	Centers for Disease Control and Prevention	2010-03	PHASE2; PHASE3
NCT01156389	COMPLETED	Malaria	Medicines for Malaria Venture	2010-07	PHASE1
NCT00699920	COMPLETED	Malaria	Sanofi	2008-06	PHASE4
NCT00285662	COMPLETED	Malaria; Anemia	Papua New Guinea Institute of Medical Research	2006-06
NCT00284687	COMPLETED	Cytomegalovirus Infections	Hadassah Medical Organization	2006-07	PHASE3
NCT00682578	COMPLETED	Uncomplicated Falciparum Malaria; Vivax Malaria	University of Oxford	2007-07	PHASE3
NCT01017770	COMPLETED	Uncomplicated P. Falciparum Malaria in Children	Centre Muraz	2008-09	PHASE4
NCT01054651	COMPLETED	Schistosoma Mansoni	Kenya Medical Research Institute	2009-10	PHASE3
NCT00393679	COMPLETED	Fever; Malaria	Institute of Tropical Medicine, Belgium	2007-07	PHASE3
NCT00493363	COMPLETED	Falciparum Malaria	University of Oxford	2007-06
NCT00639873	COMPLETED	Malaria	Medical University of Vienna	2008-06
NCT04877626	COMPLETED	P. Falciparum Malaria	Universidad Nacional de Colombia	2008-09	PHASE4
NCT00722150	COMPLETED	Falciparum Malaria	Armed Forces Research Institute of Medical Sciences, Thailand	2008-07
NCT00379821	COMPLETED	Plasmodium Falciparum Infection	National Institute of Allergy and Infectious Diseases (NIAID)	2007-02	PHASE3
NCT00894374	COMPLETED	Falciparum Malaria	Pfizer	2009-06	PHASE1
NCT00701961	COMPLETED	Plasmodium Falciparum Malaria	Institute of Tropical Medicine, Belgium	2008-10	PHASE2; PHASE3
NCT00875030	COMPLETED	Healthy Volunteers	Pfizer	2009-06	PHASE4
NCT00164255	COMPLETED	Malaria	Centers for Disease Control and Prevention	2003-01	PHASE4
NCT01567423	COMPLETED	Malaria, Falciparum	Epicentre	2008-04
NCT00297882	COMPLETED	Malaria	London School of Hygiene and Tropical Medicine	2006-07	PHASE3
NCT00231452	COMPLETED	Malaria	Hospital Clinic of Barcelona	2005-09
NCT00540410	COMPLETED	Malaria	Sanofi	2007-09	PHASE4
NCT00432367	COMPLETED	Malaria; Anaemia; Pregnancy	London School of Hygiene and Tropical Medicine	2007-02	PHASE3
NCT00694694	COMPLETED	Malaria	London School of Hygiene and Tropical Medicine	2008-06	PHASE3
NCT00697892	COMPLETED	HIV Infections; Malaria	Fran Aweeka	2005-07	PHASE1
NCT00444106	COMPLETED	Malaria; Falciparum	Novartis	2007-05	PHASE4
NCT00563914	COMPLETED	Malaria	Sanofi	2007-10	PHASE1; PHASE2
NCT00538382	COMPLETED	Malaria	NICHD Global Network for Women's and Children's Health	2007-05	PHASE1
NCT00403260	COMPLETED	Falciparum Malaria	Medicines for Malaria Venture	2007-01	PHASE3
NCT00541385	COMPLETED	Malaria	Medicines for Malaria Venture	2007-10	PHASE3
NCT00509015	COMPLETED	Malaria, Falciparum	Radboud University Medical Center	2008-02
NCT00682630	COMPLETED	Malaria	Medicines for Malaria Venture	2007-09	PHASE1
NCT00522132	COMPLETED	Malaria	Medicines for Malaria Venture	2007-09	PHASE2
NCT00550160	COMPLETED	Malaria	Kwame Nkrumah University of Science and Technology	2007-04	PHASE4
NCT01659281	COMPLETED	Plasmodium Falciparum Malaria	Armed Forces Research Institute of Medical Sciences, Thailand	2007-09
NCT00440999	COMPLETED	Malaria	Medicines for Malaria Venture	2007-03	PHASE3
NCT00422084	COMPLETED	Malaria	Medicines for Malaria Venture	2007-01	PHASE3
NCT00140361	COMPLETED	Malaria (Uncomplicated)	Centers for Disease Control and Prevention	2000-01	PHASE4
NCT00459615	COMPLETED	Falciparum Malaria; Uncomplicated Malaria	U.S. Army Office of the Surgeon General	2007-04	PHASE2
NCT00460369	COMPLETED	Uncomplicated Malaria	Institut de Recherche pour le Developpement	2007-04
NCT00298610	COMPLETED	Malaria	U.S. Army Medical Research and Development Command	2006-03	PHASE2
NCT00510159	COMPLETED	Schistosoma Haematobium	Dafra Pharma	2007-08	PHASE2; PHASE3
NCT00146731	COMPLETED	Malaria	London School of Hygiene and Tropical Medicine	2004-01	PHASE3
NCT00425763	COMPLETED	Malaria	Centers for Disease Control and Prevention	2007-05	PHASE4
NCT00356005	COMPLETED	Uncomplicated Falciparum Malaria	Medical University of Vienna	2006-08	PHASE2
NCT00344006	COMPLETED	Malaria, Falciparum	GlaxoSmithKline	2006-06	PHASE3
NCT00331708	TERMINATED	Malaria	Professor Karen I Barnes	2006-04
NCT00452907	COMPLETED	Malaria	Sanofi	2005-07	PHASE4
NCT00371735	COMPLETED	Malaria, Falciparum	GlaxoSmithKline	2006-04	PHASE3
NCT00292942	COMPLETED	Malaria; Malaria, Cerebral	U.S. Army Medical Research and Development Command	2006-06-12	PHASE1
NCT00119132	COMPLETED	Malaria	London School of Hygiene and Tropical Medicine	2005-06	PHASE2; PHASE3
NCT00386503	COMPLETED	Malaria	Sanofi	2006-06	PHASE1
NCT00331136	COMPLETED	Uncomplicated Plasmodium Falciparum Malaria	Medicines for Malaria Venture	2006-06	PHASE2
NCT00123552	COMPLETED	Malaria	University of California, San Francisco	2004-11	PHASE3
NCT00111163	COMPLETED	Malaria; Anemia	Centers for Disease Control and Prevention	2004-03
NCT01594931	COMPLETED	Plasmodium Falciparum Malaria	Medicines for Malaria Venture	2005-07	PHASE2
NCT00386750	TERMINATED	Malaria; Falciparum	Novartis Pharmaceuticals	2005-06	PHASE4
NCT00164359	COMPLETED	Malaria, Falciparum	Centers for Disease Control and Prevention	2005-04	PHASE4
NCT00164710	COMPLETED	Malaria, Falciparum	Centers for Disease Control and Prevention	2005-04	PHASE4
NCT03768908	COMPLETED	Plasmodium Falciparum Malaria	Professor Anders Björkman	2005-01-05	PHASE4
NCT00299208	COMPLETED	Plasmodium Falciparum Malaria	National Institute of Allergy and Infectious Diseases (NIAID)		PHASE2
NCT00203801	COMPLETED	Malaria	University of Cape Town	2002-01
NCT00373607	COMPLETED	Malaria	Institute of Tropical Medicine, Belgium	2003-07	PHASE3
NCT00959517	COMPLETED	Uncomplicated Falciparum Malaria	London School of Hygiene and Tropical Medicine	2001-07	PHASE2
NCT00519467	COMPLETED	Malaria	GlaxoSmithKline	2003-06	PHASE2
NCT03764527	COMPLETED	Plasmodium Falciparum Malaria	Professor Anders Björkman	2002-11-01	PHASE4
NCT00378625	COMPLETED	Malaria,Falciparum; Malaria; Antimalarials	Centro Internacional de Entrenamiento e Investigaciones Médicas	2000-04	PHASE3
NCT00484900	COMPLETED	Plasmodium Falciparum Malaria	Dafra Pharma	2006-05	PHASE3
NCT00646126	COMPLETED	Plasmodium Falciparum; Asymptomatic Parataemia; Sub Patent Parasitaemia	Tropical Medicine Research Institute	2005-08	PHASE3
NCT00118807	COMPLETED	Malaria	London School of Hygiene and Tropical Medicine	2003-08	PHASE3
NCT00287300	COMPLETED	Malaria	University of North Carolina	2003-09
NCT00316329	COMPLETED	Malaria	Sanofi	2006-03	PHASE3
NCT00132561	COMPLETED	Malaria	London School of Hygiene and Tropical Medicine	2002-06	PHASE2; PHASE3
NCT00479206	COMPLETED	Malaria, Falciparum	Medical University of Vienna	2006-10
NCT00119145	COMPLETED	Malaria	London School of Hygiene and Tropical Medicine	2005-06	PHASE4
NCT00461578	COMPLETED	Malaria	London School of Hygiene and Tropical Medicine	2005-04
NCT00238017	UNKNOWN	Malaria	Charite University, Berlin, Germany	2005-10	PHASE4
NCT00330902	COMPLETED	Plasmodium Infections	London School of Hygiene and Tropical Medicine	2004-01	PHASE3
NCT00978172	COMPLETED	Malaria	Mepha Ltd.	2007-12	PHASE4
NCT01204411	WITHDRAWN	Malaria, Falciparum; Malnutrition; Child	Epicentre		PHASE4
NCT00445796	COMPLETED	Malaria	Sanofi	2005-06	PHASE4
NCT00354380	COMPLETED	Malaria	Heidelberg University	2006-09	PHASE2
NCT00289250	COMPLETED	Asymptomatic P.Falciparum Malaria	London School of Hygiene and Tropical Medicine	2001-05	PHASE3
NCT00465257	SUSPENDED	Malaria	Karolinska University Hospital	2007-05	PHASE4
NCT00203736	COMPLETED	Malaria	University of Cape Town	2003-01
NCT00243737	COMPLETED	Malaria	Albert Schweitzer Hospital	2005-10	PHASE2
NCT00374205	TERMINATED	Malaria, Falciparum	Bernhard Nocht Institute for Tropical Medicine	2006-09	PHASE4
NCT00203814	COMPLETED	Malaria	University of Cape Town	2004-01
NCT00158548	COMPLETED	Malaria; Falciparum Malaria; Vivax Malaria	London School of Hygiene and Tropical Medicine	2001-06	PHASE3
NCT00545935	COMPLETED	Malaria	Heidelberg University	2007-07	PHASE2
NCT00132548	COMPLETED	Malaria	London School of Hygiene and Tropical Medicine	2004-06	PHASE3
NCT00292929	COMPLETED	Malaria; Malaria, Cerebral	U.S. Army Medical Research and Development Command		PHASE1
NCT00157885	COMPLETED	Malaria, Falciparum; Malaria, Vivax	Menzies School of Health Research	2005-07
NCT00406146	UNKNOWN	Uncomplicated Malaria	University of Ghana Medical School	2004-10	PHASE3
NCT00486694	COMPLETED	Malaria, Vivax	London School of Hygiene and Tropical Medicine	2004-03	PHASE2
NCT00127998	COMPLETED	Malaria	Centers for Disease Control and Prevention	2005-07

(data from https://clinicaltrials.gov, updated on 2025-07-31)

Check the Artesunate product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Artesunate potently inhibits exported protein 1 (EXP1) and modulates STAT3 signal transduction pathways, thereby impairing essential metabolic transport mechanisms and triggering selective apoptosis in targeted pathogenic and neoplastic cells. This targeted cellular toxicity directly underlies its therapeutic efficacy in reducing parasite burdens and inhibiting abnormal cell proliferation, supporting its clinical application and investigation for severe malaria, human papillomavirus-associated anal dysplasia, and various malignancies.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).